All News

Tigilanol tiglate is a novel, small molecule drug for the intratumoral treatment of solid tumors, inducing tumor cell death and stimulating immune response.

Taking a few seconds to double-check a prescription can have significant impacts on patient safety

Tucatinib significantly improved median PFS in the overall population and those with brain metastases.

The complexity of the disease and number of treatment options can necessitate a personalized approach.

With a wide array of OTC products, pharmacists can help patients select the right regimen

One significant difference was an increased rate of bupropion prescriptions for transgender females.

This episode highlights strategies for pharmacists and pharmacies to address social determinants of health barriers through leveraging PQA's SDOH Resource Guide.

Sustained cognitive improvement is likely a result of lower inflammation, remission of comorbidities, higher physical activity, and better mood.

The authors emphasize that further research on a diverse population that focuses on the role of duration and lifestyle choices and neuroinflammatory markers should be performed.

Since the first FDA biosimilar approval of filgrastim-sndz (Zarxio) in 2015, a total of 44 biosimilars for 15 originator products have been approved and more than 20 are marketed.

The oral therapy is available through a REMS program.

Finding simple solutions to improve movement during the day can make important differences to their overall health

This frequency can allow for faster observation of toxicities and adherence issues.

Nabila Ismail, PharmD, shares her journey as a travel and lifestyle creator

Nutrition is foundational to health, but healthy eating does not look the same for everyone.

The researchers made a connection between positive outcomes for infectious disease patients, higher reimbursement class, and the presence of pharmacists in care teams.

This episode provides a brief overview of California's new Stop Dangerous Pharmacies Act, the benefits of e-prescribing for improving patient safety and outcomes, and New Jersey's pilot program for anonymous dispensing of opioid antidotes from pharmacies.

The approval of irinotecan liposome offers an improved first-line treatment option for individuals diagnosed with metastatic pancreatic adenocarcinoma.

Iloprost had also received Priority Review and Orphan Drug Designations for this indication, and FDA approval in 2004 for the treatment of pulmonary arterial hypertension.

Researchers will continue to research how lantibiotic’s antimicrobial effects can be harnessed for good.

Continued doses of denosumab reduced the incidence of diabetes by more than 1000 patients compared to an initial dose alone.

This review summarizes current utilization of anti-HER2 targeted therapy across several non-breast solid tumors in the setting of advanced disease.

In a projective model, tirzepatide saved patients more than $15,000 per quality-adjusted life-year.

Despite the growth in vaccine and antibody development for combatting RSV, lower income countries may not reap the benefits.

In this model, community pharmacists deliver all aspects of treating HCV infection in individuals who inject drugs.

Repotrectinib led to a durable anti-tumor response in patients with NTRK-positive locally advanced or metastatic solid tumors.

This accreditation allows pharmacists to give diabetes education to patients with Medicare and receive Medicare reimbursement.